Seres Therapeutics Inc To Discuss Topline Results From The Phase 2b ECO-RESET Study Evaluating SER-287 In Patients With Mild-To-Moderate Ulcerative Colitis Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Seres Therapeutics Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Dr. Carlo Tanzi of Investor Relations. Please go ahead, sir.
Thank you, and good morning. A press release announcing top line results from the SER-287 Phase IIb clinical study in patients with mild to moderate ulcerative colitis became available at 7 a.m. Eastern Time this morning and can be found on the Investors & News section of the company's website.
I'd like to remind you that we'll be making forward-looking statements relating to the potential impact of microbiome therapeutics; the safety, efficacy, regulatory and clinical progress of our product candidates; plans, timing and potential impact of the release of additional preclinical and clinical data, including the SER-287
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
